血清糖基化纤连蛋白与血管生成因子预测慢性高血压孕妇发生重叠型子痫前期的效果比较
本研究为前瞻性研究,纳入104例孕24-41周慢性高血压单胎孕妇,其中26例(25.0%)在采样后2周内发生重叠型子痫前期。在约10%筛查阳性率下,GlyFn、PlGF及sFlt-1/PlGF比值对重叠型子痫前期的预测性能相似,检出率约23-27%。作者认为GlyFn为无需实验室的床旁快速检测,但三者预测性能均较差,不太可能改善慢性高血压孕妇的管理。
要点
- 104例慢性高血压单胎孕妇中26例(25.0%)在采样后2周内发生重叠型子痫前期。
- 在筛查阳性率11%、假阳性率约5%时,三种标志物检出率约23-27%,预测性能相似。
- GlyFn为床旁检测,10分钟内出结果,但作者认为三者预测性能均较差,不太可能改善管理。
核心结论
- GlyFn检测为无需实验室的简单床旁检测,可在测试后10分钟内出结果,就此而言可能替代目前用于高危孕妇临近子痫前期预测的血管生成标志物。
- 但GlyFn和血管生成因子对重叠型子痫前期的预测性能均较差,不太可能改善慢性高血压孕妇的管理。
研究设计与样本
- 前瞻性研究,纳入104例孕24-41周慢性高血压单胎孕妇,其中26例(25.0%)在采样后2周内发生重叠型子痫前期。
- 在约10%固定筛查阳性率下比较GlyFn、PlGF及sFlt-1/PlGF比值对重叠型子痫前期的预测性能。
主要发现
- 采样时中位孕周为34.1周(四分位距31.5-35.6周),84.6%(88/104)的病例在<36周采样。
- 在筛查阳性率11%、假阳性率约5%时,三种筛查方法对重叠型子痫前期的检出率约为23-27%,预测性能相似。
关键数值与推荐
- GlyFn为床旁检测,无需实验室,测试后10分钟内出结果。
- 在筛查阳性率约10%下比较三种标志物的预测性能。
局限性
- 作者指出GlyFn和血管生成因子对重叠型子痫前期的预测性能均较差,不太可能改善慢性高血压孕妇的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the predictive performance for delivery with pre-eclampsia (PE) within 2 weeks of assessment in women with chronic hypertension at 24-41 weeks' gestation between serum glycosylated fibronectin (GlyFn) concentration, serum placental growth factor (PlGF) concentration and soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF concentration ratio. METHODS: This was a prospective study of 104 women with a singleton pregnancy and chronic hypertension presenting at 24-41 weeks' gestation. Twenty-six (25.0%) cases developed superimposed PE within 2 weeks of sampling. We compared the predictive performance for superimposed PE between GlyFn, PlGF and the sFlt-1/PlGF ratio at a fixed screen-positive rate of approximately 10%. RESULTS: The median gestational age at sampling was 34.1 (interquartile range, 31.5-35.6) weeks and 84.6% (88/104) of cases were sampled at < 36 weeks. The predictive performance for superimposed PE of the three methods of screening was similar, with detection rates of about 23-27%, at a screen-positive rate of 11% and a false-positive rate of about 5%. CONCLUSIONS: Measurement of GlyFn is a simple point-of-care test that can be carried out without need for a laboratory and provide results within 10 min of testing. In this respect, it could potentially replace the angiogenic markers that are used currently in the prediction of imminent PE in high-risk women. However, neither GlyFn nor angiogenic factors are likely to improve the management of women with chronic hypertension because their predictive performance for superimposed PE is poor. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Sokratous N, Bednorz M, Syngelaki A, et al. Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre-eclampsia in women with chronic hypertension. Ultrasound Obstet Gynecol. 2023. PMID: 37675881. doi:10.1002/uog.27475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。